ClinicalTrials.gg
CompletedNCT03299946Updated Sep 3, 2024

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

A Phase 1 interventional study of Cabozantinib and Nivolumab in Locally Advanced Hepatocellular Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.

Primary conditionCarcinoma, HepatocellularRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's listed conditions name Carcinoma, Hepatocellular, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.

Enrollment
22nd of 27
15 · median 35
Started
2018
with 3 others
Phase 1
3 of 27
none open now
Registered
6th of 27
by date

Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 22nd largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 1, and was the 6th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cabozantinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The proposed study is an open-label, single institution, single arm phase 1b study of neoadjuvant cabozantinib plus nivolumab in patients with locally advanced HCC.

03

Conditions studied

  • Locally Advanced Hepatocellular Carcinoma

Browse trials for

Keywords

  • Nivolumab
  • Cabozantinib
  • Neoadjuvant
  • Immunotherapy
  • Liver Cancer
  • Borderline Resectable
  • Advance Resectable
  • Neoplasms
  • Hepatocellular Carcinoma
  • HCC
  • Resection
04

In context

Carcinoma, Hepatocellular Reclassified

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

This study's enrollment of 15 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have locally advanced/borderline resectable hepatocellular carcinoma.
  2. Must have .
  3. Age ≥18 years.
  4. (ECOG) performance status 0 or 1.
  5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  6. Patients must have adequate liver remnant and function.
  7. Antiviral therapy per local standard of care for .
  8. Woman of child bearing potential must have a negative pregnancy test.
  9. Must use acceptable form of while on study.
  10. Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar carcinoma or mixed HCC.
  2. Chemotherapy, radiotherapy, therapy, or surgery less than 6 months prior to trial registration.
  3. Concomitant Anticoagulation therapy.
  4. Any GI or pulmonary risks of bleeding.
  5. History of Infection.
  6. Active co-infection with and .
  7. Active co-infection with hepatitis B and hepatitis D.
  8. Has a diagnosis of immunodeficiency, or is receiving systemic therapy.
  9. History of any disease requiring systemic treatment within the past 2 years. Any patient bearing an allograft is not eligible.
  10. Any additional with treatment or life-limiting cancers. Superficial bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring therapy would not exclude participation in this trial.
  11. Uncontrolled intercurrent illness.
  12. interval calculated by the Fridericia formula.
  13. Uncontrolled high blood pressure.
  14. Are pregnant or breastfeeding.
  15. Any gastrointestinal (GI) disorders.
  16. Any certain study-specified heart conditions 6 months prior to enrollment.
  17. Major surgery within 2 months before enrollment.
  18. Have any evidence of moderate or severe ascites.
  19. Any untreated or incompletely treated varices with bleeding or high-risk bleeding.
  20. Inability to swallow intact tablets.
  21. Known or suspected to study treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Cabozantinib · Drug: Nivolumab

Interventions

  • Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.

    Also known as: XL184

  • Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.

    Also known as: OPDIVO, BMS 936558, MDX-1106, ONO-4538

07

What researchers measure

Primary outcomes

  1. Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.

    Time frame: 4 years

  2. Number of patients who complete pre-op treatment and proceed to surgery.

    Time frame: 4 years

Secondary outcomes

  1. Percentage of participants who obtain R0 resection.

    Time frame: 4 years

  2. Percentage of participants who obtain a pathologic complete response (CR).

    Time frame: 4 years

  3. Percentage of participants who obtain a major pathologic responses (MPR)

    Time frame: 4 years

  4. Objective response rate (ORR)

    Time frame: 4 years

  5. Median Overall Survival (OS)

    Time frame: 5 years

  6. Disease free survival (DFS)

    Time frame: 5 years

08

Study locations

1 site
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
09

References and documents

Publications

  • Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29. PubMed 34796337 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2019, 18 months.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's 18 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 3, 2017
StartActual
May 14, 2018
Primary completionActual
Dec 9, 2019
CompletionActual
Oct 1, 2021
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03299946
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
May 14, 2018
Primary completion
Dec 9, 2019
Completion
Oct 1, 2021
Last update
Sep 3, 2024

Study contacts

Daniel Laheru, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Nivolumab

Start the discussion